Outcomes of Second Anti-CD19 CAR T-Cell Therapy (CART2) in Acute B Lymphoblastic Leukemia and the Impact of Allo-HSCT on Efficacy.

Cell Transplant · 2023 · PMC10585987 · PMID 37846503

Europe PMC DOI

hedged sentence

0.1030

closest p · 2.1× alpha

0.1030

boldest claim

The sentences

did not reach statistical significanceP = 0.103not close (p > 0.1)

2F ) revealed that the CR rate of CART2 administered to patients who relapsed after CART1 bridging allo-HSCT was higher than that of group 2, although the difference did not reach statistical significance ( P = 0.103).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.